---
title: "Jiangxi Bio rises 8% on vet antitoxin approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292716396.md"
description: "Jiangxi Bio climbed 8.64% to HK$4.890 in Hong Kong trading after a subsidiary received approval for veterinary tetanus antitoxin."
datetime: "2026-07-15T05:40:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292716396.md)
  - [en](https://longbridge.com/en/news/292716396.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292716396.md)
generator: "portal-rs"
---

# Jiangxi Bio rises 8% on vet antitoxin approval

Jiangxi Bio (6915.HK) **climbed** **8%** during regular trading to **HK$4.890**.

The surge followed news that a subsidiary recently received approval for veterinary tetanus antitoxin, serving as the primary catalyst for the stock's movement.

### Related Stocks

- [06915.HK](https://longbridge.com/en/quote/06915.HK.md)

## Related News & Research

- [August Surge: Funds are Paying an "Extra Premium" for Leading Crypto Treasury Companies](https://longbridge.com/en/news/298123426.md)
- [CStone Pharma shares added to Southbound Stock Connect eligible list](https://longbridge.com/en/news/298144786.md)
- [SinoMab Shareholders Unanimously Back Disposal Deal at Extraordinary Meeting](https://longbridge.com/en/news/298198250.md)
- [LongBio Pharma added to Shanghai, Shenzhen-Hong Kong Stock Connect eligible lists](https://longbridge.com/en/news/298219043.md)
- [Shaanxi Micot H shares join Shanghai and Shenzhen Stock Connect eligible list](https://longbridge.com/en/news/298218762.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**